Inventiva S.A. (NASDAQ: IVA)

Описание: Inventiva S.A. (IVA) is a clinical-stage biopharmaceutical company based in France. The company specializes in developing oral small molecule therapies for diseases with significant unmet medical needs, particularly in the areas of fibrosis, lysosomal storage disorders, and oncology.

Key Product Candidates

**Lanifibranor**: This is Inventiva's lead product candidate. It is a novel pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist. PPARs play a crucial role in controlling metabolic, inflammatory, and fibrotic processes. Lanifibranor is currently being investigated in the pivotal Phase 3 NATiV3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. The company has announced the completion of patient enrollment for the NATiV3 trial, with topline results expected in the second half of 2026.
**Odiparcil**: This is another clinical-stage program for the treatment of mucopolysaccharidoses (MPS), a group of rare genetic disorders.

Corporate and Financial Information

**Ticker**: IVA (listed on NASDAQ) and also on Euronext Paris (EPA: IVA).
**Headquarters**: Daix, France.
**Market Cap**: As of early September 2025, the market capitalization was approximately $796 million.
**Financials**: The company reported no revenues in the first quarter of 2025 and operates with a negative EBITDA.
**Recent Events**:
Inventiva completed enrollment in its Phase 3 NATiV3 clinical trial for lanifibranor in MASH patients in April 2025.
In May 2025, Inventiva secured a second tranche of a structured financing agreement, raising €115.6 million to fund the NATiV3 trial and extend its operational runway.
The company has received Breakthrough Therapy and Fast Track designation from the FDA for lanifibranor for the treatment of MASH.
The company has a portfolio of pre-clinical therapy programs and also has research partnerships with other pharmaceutical companies like AbbVie and Sino Biopharm.